05.03.2020 • NewsDede WillamsDSM

DSM Upgrades High-end US Compounding Plant

DSM Upgrades High-end US Compounding Plant (c) DSM
DSM Upgrades High-end US Compounding Plant (c) DSM

Dutch chemicals, plastics and life sciences group DSM is increasing capacity at its US high performance materials compounding facility located at Evansville in the US state of Indiana.

The upgrade, by an undisclosed margin, is due to be completed in the third quarter of 2021. No investment cost has been disclosed.

DSM said the modernized and expanded site will be equipped to produce the next generation of advanced materials, including bio-based thermoplastics, and will help meet increased demand for its PA 6 /PA 6.6, PET/PBT compounds and its high-end PA compounds as well as for PPA. 

The group’s engineering plastics arm, which said the expansion is being driven by increasing demand from multiple industries for advanced material solutions, in particular for applications in electrification, metal replacement and lightweighting, plans to use latest state-of-the-art production technologies to increase efficiency and sustainability.

Shruti Singhal, president of DSM Engineering Plastics, said the company’s new project reinforces its focus on North America as a key growth market for its business as well as its commitment to continuously improving the technology and sustainability of its facilities worldwide.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.